Maureen Dubreuil1, Yanyan Zhu2, Yuqing Zhang2, John D Seeger3, Na Lu2, Young Hee Rho2, Hyon K Choi4. 1. Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA Rheumatology Division, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA. 2. Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA. 3. Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA. 4. Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Allopurinol is the most commonly used urate-lowering therapy, with rare but potentially fatal adverse effects. However, its impact on overall mortality remains largely unknown. In this study, we evaluated the impact of allopurinol initiation on the risk of mortality among individuals with hyperuricaemia and among those with gout in the general population. METHODS: We conducted an incident user cohort study with propensity score matching using a UK general population database. The study population included individuals aged ≥40 years who had a record of hyperuricaemia (serum urate level >357 μmol/L for women and >416 μmol/L for men) between January 2000 and May 2010. To closely account for potential confounders of allopurinol use and risk of death, we constructed propensity score matched cohorts of allopurinol initiators and comparators (non-initiators) within 6-month cohort accrual blocks. RESULTS: Of 5927 allopurinol initiators and 5927 matched comparators, 654 and 718, respectively, died during the follow-up (mean=2.9 years). The baseline characteristics were well balanced in the two groups, including the prevalence of gout in each group (84%). Allopurinol initiation was associated with a lower risk of all-cause mortality (matched HR 0.89 (95% CI 0.80 to 0.99)). When we limited the analysis to those with gout, the corresponding HR was 0.81 (95% CI 0.70 to 0.92). CONCLUSIONS: In this general population study, allopurinol initiation was associated with a modestly reduced risk of death in patients with hyperuricaemia and patients with gout. The overall benefit of allopurinol on survival may outweigh the impact of rare serious adverse effects. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Allopurinol is the most commonly used urate-lowering therapy, with rare but potentially fatal adverse effects. However, its impact on overall mortality remains largely unknown. In this study, we evaluated the impact of allopurinol initiation on the risk of mortality among individuals with hyperuricaemia and among those with gout in the general population. METHODS: We conducted an incident user cohort study with propensity score matching using a UK general population database. The study population included individuals aged ≥40 years who had a record of hyperuricaemia (serum urate level >357 μmol/L for women and >416 μmol/L for men) between January 2000 and May 2010. To closely account for potential confounders of allopurinol use and risk of death, we constructed propensity score matched cohorts of allopurinol initiators and comparators (non-initiators) within 6-month cohort accrual blocks. RESULTS: Of 5927 allopurinol initiators and 5927 matched comparators, 654 and 718, respectively, died during the follow-up (mean=2.9 years). The baseline characteristics were well balanced in the two groups, including the prevalence of gout in each group (84%). Allopurinol initiation was associated with a lower risk of all-cause mortality (matched HR 0.89 (95% CI 0.80 to 0.99)). When we limited the analysis to those with gout, the corresponding HR was 0.81 (95% CI 0.70 to 0.92). CONCLUSIONS: In this general population study, allopurinol initiation was associated with a modestly reduced risk of death in patients with hyperuricaemia and patients with gout. The overall benefit of allopurinol on survival may outweigh the impact of rare serious adverse effects. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: L Grimaldi-Bensouda; A Alpérovitch; E Aubrun; N Danchin; M Rossignol; L Abenhaim; P Richette Journal: Ann Rheum Dis Date: 2014-01-06 Impact factor: 19.103
Authors: Seoyoung C Kim; Craig Newcomb; David Margolis; Jason Roy; Sean Hennessy Journal: Arthritis Care Res (Hoboken) Date: 2013-04 Impact factor: 4.794
Authors: Wolfram Doehner; Nina Schoene; Mathias Rauchhaus; Francisco Leyva-Leon; Darrell V Pavitt; David A Reaveley; Gerhard Schuler; Andrew J S Coats; Stefan D Anker; Rainer Hambrecht Journal: Circulation Date: 2002-06-04 Impact factor: 29.690
Authors: Lisa K Stamp; William J Taylor; Peter B Jones; Jo L Dockerty; Jill Drake; Christopher Frampton; Nicola Dalbeth Journal: Arthritis Rheum Date: 2012-08
Authors: Colin A J Farquharson; Robert Butler; Alexander Hill; Jill J F Belch; Allan D Struthers Journal: Circulation Date: 2002-07-09 Impact factor: 29.690
Authors: Giuseppe Mercuro; Cristiana Vitale; Elena Cerquetani; Sandra Zoncu; Martino Deidda; Massimo Fini; Giuseppe M C Rosano Journal: Am J Cardiol Date: 2004-10-01 Impact factor: 2.778
Authors: Jean W Liew; Christine Peloquin; Sara K Tedeschi; David T Felson; Yuqing Zhang; Hyon K Choi; Robert Terkeltaub; Tuhina Neogi Journal: Arthritis Care Res (Hoboken) Date: 2022-03-04 Impact factor: 5.178